In a recent update, Canaccord Genuity analyst Sumant Kulkarni has maintained a "Hold" rating on Sage Therapeutics (SAGE, Financial). The commitment to this rating comes as part of the analyst's ongoing evaluation of the company's performance and prospects.
Notably, there has been a change in the price target for Sage Therapeutics. The price target has been raised from a previous $8.00 USD to a new $8.50 USD. This adjustment represents a 6.25% increase in the price target for (SAGE, Financial), reflecting updated expectations by the analyst concerning the company's potential market performance.
The rating from Canaccord Genuity remains consistent, with the analyst choosing to uphold a "Hold" stance on SAGE shares. This recommendation suggests that the stock's current market price is within a fair value range as per the evaluation by the analyst, and investors are advised to retain their holdings without making additional investments at this time.
Investors and market watchers are encouraged to note these developments as they consider their strategy with Sage Therapeutics (SAGE, Financial), and stay attuned to further updates that might influence future stock performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 16 analysts, the average target price for Sage Therapeutics Inc (SAGE, Financial) is $8.52 with a high estimate of $12.00 and a low estimate of $5.00. The average target implies an downside of 6.06% from the current price of $9.07. More detailed estimate data can be found on the Sage Therapeutics Inc (SAGE) Forecast page.
Based on the consensus recommendation from 17 brokerage firms, Sage Therapeutics Inc's (SAGE, Financial) average brokerage recommendation is currently 2.9, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Sage Therapeutics Inc (SAGE, Financial) in one year is $182.36, suggesting a upside of 1910.58% from the current price of $9.07. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Sage Therapeutics Inc (SAGE) Summary page.
